Tempus AI, Inc. (TEM)
| Market Cap | 8.95B -3.3% |
| Revenue (ttm) | 1.36B +69.8% |
| Net Income | -302.91M |
| EPS | -1.72 |
| Shares Out | 179.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,691,015 |
| Open | 49.35 |
| Previous Close | 49.47 |
| Day's Range | 46.75 - 49.89 |
| 52-Week Range | 41.73 - 104.32 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 71.69 (+43.78%) |
| Earnings Date | May 5, 2026 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $71.69, which is an increase of 43.78% from the latest price.
News
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400....
Tempus AI announces proposed convertible senior notes offering
Tempus AI (TEM) announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 in a private
Cathie Wood’s ARK Investment buys 146K shares of Tempus AI today
20:02 EDT Cathie Wood’s ARK Investment buys 146K shares of Tempus AI (TEM) today
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer,...
Tempus AI price target lowered to $59 from $68 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Tempus AI (TEM) to $59 from $68 and keeps an Outperform rating on the shares. The firm updated its
Tempus AI price target raised to $68 from $65 at TD Cowen
TD Cowen raised the firm’s price target on Tempus AI (TEM) to $68 from $65 and keeps a Buy rating on the shares. The firm said its strong growth was
Lucent Diagnostics announces collaboration with Tempus AI
Lucent Diagnostics, a brand of Quanterix Corporation (QTRX), announced a collaboration with Tempus AI (TEM) to broaden access to a novel blood-based biomarker panel designed to improve detection accur...
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading ...
Tempus AI reports Q1 adjusted EPS (13c), consensus (20c)
Reports Q1 revenue $348.1M, consensus $345.44M. “Our strong financial and operational performance this quarter underscores the accelerating demand for our AI-driven diagnostic platform and the immense...
Tempus AI raises FY26 revenue view to $1.59B-$1.6B from $1.59B, consensus $1.59B
Backs FY26 adjusted EBITDA view roughly $65M.
Tempus AI Earnings Call Transcript: Q1 2026
Revenue grew 36% year-over-year to $348.1 million, led by strong oncology and data businesses. Guidance was raised to $1.59–$1.6 billion in revenue and $65 million adjusted EBITDA for 2026, with robust growth in strategic pharma collaborations and improving cash flow expected.
Tempus Reports First Quarter 2026 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...
Tempus to Host Inaugural Investor Day on May 29, 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Fr...
Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been nam...
Tempus, USC announce strategic collaboration to accelerate precision medicine
Tempus AI (TEM) and Keck School of Medicine of USC and Keck Medicine of USC announced a multi-faceted collaboration aimed at advancing patient care and accelerating research through the power
Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC,...
Tempus to Report First Quarter 2026 Financial Results on May 5
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first q...
Tempus AI, Predicta Biosciences announces expansion of GenoPredicta
Tempus AI (TEM) and Predicta Biosciences announced the commercial expansion of a co-branded whole-genome sequencing, WGS, assay, currently known as GenoPredicta, intended for the comprehensive genomic...
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developin...
Tempus AI Transcript: 25th Annual Needham Virtual Healthcare Conference
The session highlighted strong growth in diagnostics, especially oncology, and robust expansion in the data business with over $1.1 billion in TCV and new strategic collaborations. Ongoing investments in AI applications and platform tools, along with a disciplined capital allocation strategy, position the company for continued growth.
Tempus AI announces 31 abstracts for presentation at AACR annual meeting
Tempus AI (TEM) announced the acceptance of 31 abstracts-including one oral presentation-for the American Association for Cancer Research Annual Meeting 2026 taking place April 17-22 in San Diego. Tem...
Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one ora...
tempus AI Inc Class A call volume above normal and directionally bullish
Bullish option flow detected in tempus AI (TEM) Inc Class A with 14,076 calls trading, 1.3x expected, and implied vol increasing over 1 point to 75.75%. May-26 50 calls and
Tempus AI launches automated ‘Active Follow-Up’ service
Tempus AI (TEM) announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an “active follow-up” track. This integrated workflow ...
Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update servi...